Tranexamic Acid for Melasma and Hyperpigmentation — Skin & Hair
Tranexamic acid is a synthetic lysine analog that inhibits the plasminogen/plasmin pathway to reduce melanocyte stimulation, offering a targeted approach for melasma and post-inflammatory hyperpigmentation.
Overview
Tranexamic acid (TXA) has rapidly emerged as a cornerstone treatment for melasma and recalcitrant hyperpigmentation disorders. Originally developed as an antifibrinolytic agent, TXA inhibits plasminogen activator in keratinocytes, which reduces the release of arachidonic acid and prostaglandins that stimulate melanocyte activity. A pivotal RCT published in JAMA Dermatology (2020) demonstrated that oral TXA 250mg BID significantly reduced melasma severity (MASI score) compared to placebo. Topical formulations at 2-5% concentrations show moderate evidence for pigmentation reduction with fewer systemic risks. The compound works through multiple mechanisms: blocking UV-induced plasmin activity, reducing mast cell-melanocyte interactions, and inhibiting endothelin-1 and stem cell factor release. TXA is particularly effective for the vascular component of melasma, distinguishing it from conventional tyrosinase inhibitors. It can be administered orally, topically, or via intradermal microinjection.
Indications
- Melasma (epidermal, dermal, and mixed types)
- Post-inflammatory hyperpigmentation
- Solar lentigines and age spots
- Recalcitrant pigmentation unresponsive to hydroquinone
- Erythema and vascular component of melasma
- Periorbital hyperpigmentation
Mechanism of Action
TXA competitively inhibits plasminogen activator in keratinocytes, preventing conversion of plasminogen to plasmin and reducing arachidonic acid release that stimulates melanocytes
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Tranexamic Acid | 250 mg | Twice daily | JAMA Dermatology 2020 RCT dose; 12-week course, reassess for continuation |
| Tranexamic Acid | 3-5% | Twice daily | Applied to affected areas; minimal systemic absorption; safe long-term |
| Tranexamic Acid | 4 mg/mL (0.1 mL per injection point) | Every 2-4 weeks for 3-6 sessions | Direct delivery to dermis; effective for dermal melasma; physician-administered |
Evidence Grade
GRADE C
Safety & Contraindications
- Oral use: rare risk of thromboembolic events; contraindicated in patients with history of DVT, PE, or active thromboembolic disease
- Screen for thrombotic risk factors before initiating oral therapy
- Topical formulations have minimal systemic absorption and excellent safety profile
- Avoid concurrent use with combined oral contraceptives (increased thrombotic risk with oral TXA)
- Mild GI symptoms (nausea, abdominal discomfort) reported in 5-10% of oral users
- Intradermal injections may cause transient erythema and rare ecchymosis
- Not recommended during pregnancy or lactation